March 16, 2012 — Novelos Therapeutics Inc. announced that the University of Wisconsin Carbone Cancer Center, a medical oncology research institution, enrolled the first patient in a Phase 1-2 positron emission tomography (PET) imaging trial of I-124-CLR1404 (LIGHT), a cancer-targeted PET imaging agent, in patients with primary or metastatic brain cancer.